South Korea · Delayed Price · Currency is KRW Wonbiogen Statistics
Total Valuation
Wonbiogen has a market cap or net worth of KRW 41.31 billion. The enterprise value is 34.61 billion.
| Market Cap | 41.31B |
| Enterprise Value | 34.61B |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Wonbiogen has 6.81 million shares outstanding. The number of shares has decreased by -1.64% in one year.
| Current Share Class | 6.81M |
| Shares Outstanding | 6.81M |
| Shares Change (YoY) | -1.64% |
| Shares Change (QoQ) | -1.73% |
| Owned by Insiders (%) | 33.72% |
| Owned by Institutions (%) | n/a |
| Float | 4.51M |
Valuation Ratios
The trailing PE ratio is 5.03.
| PE Ratio | 5.03 |
| Forward PE | n/a |
| PS Ratio | 1.09 |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 3.94 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 4.11 |
| EV / Sales | 0.92 |
| EV / EBITDA | 3.14 |
| EV / EBIT | 3.65 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.10.
| Current Ratio | 3.25 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | -3.05 |
| Interest Coverage | 185.64 |
Financial Efficiency
Return on equity (ROE) is 20.07% and return on invested capital (ROIC) is 23.29%.
| Return on Equity (ROE) | 20.07% |
| Return on Assets (ROA) | 12.31% |
| Return on Invested Capital (ROIC) | 23.29% |
| Return on Capital Employed (ROCE) | 20.61% |
| Weighted Average Cost of Capital (WACC) | 6.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.77 |
| Inventory Turnover | 2.92 |
Taxes
In the past 12 months, Wonbiogen has paid 1.65 billion in taxes.
| Income Tax | 1.65B |
| Effective Tax Rate | 16.38% |
Stock Price Statistics
The stock price has increased by +9.37% in the last 52 weeks. The beta is 0.55, so Wonbiogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +9.37% |
| 50-Day Moving Average | 5,691.00 |
| 200-Day Moving Average | 6,501.95 |
| Relative Strength Index (RSI) | 52.82 |
| Average Volume (20 Days) | 18,978 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Wonbiogen had revenue of KRW 37.80 billion and earned 8.42 billion in profits. Earnings per share was 1,207.12.
| Revenue | 37.80B |
| Gross Profit | 19.56B |
| Operating Income | 9.62B |
| Pretax Income | 10.07B |
| Net Income | 8.42B |
| EBITDA | 11.16B |
| EBIT | 9.62B |
| Earnings Per Share (EPS) | 1,207.12 |
Balance Sheet
The company has 11.15 billion in cash and 4.55 billion in debt, with a net cash position of 6.61 billion or 970.60 per share.
| Cash & Cash Equivalents | 11.15B |
| Total Debt | 4.55B |
| Net Cash | 6.61B |
| Net Cash Per Share | 970.60 |
| Equity (Book Value) | 44.67B |
| Book Value Per Share | 6,578.12 |
| Working Capital | 16.19B |
Cash Flow
In the last 12 months, operating cash flow was 10.49 billion and capital expenditures -11.98 billion, giving a free cash flow of -1.49 billion.
| Operating Cash Flow | 10.49B |
| Capital Expenditures | -11.98B |
| Depreciation & Amortization | 1.54B |
| Net Borrowing | 3.19B |
| Free Cash Flow | -1.49B |
| FCF Per Share | -218.77 |
Margins
Gross margin is 51.74%, with operating and profit margins of 25.45% and 22.28%.
| Gross Margin | 51.74% |
| Operating Margin | 25.45% |
| Pretax Margin | 26.64% |
| Profit Margin | 22.28% |
| EBITDA Margin | 29.51% |
| EBIT Margin | 25.45% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 140.00, which amounts to a dividend yield of 2.28%.
| Dividend Per Share | 140.00 |
| Dividend Yield | 2.28% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 11.71% |
| Buyback Yield | 1.64% |
| Shareholder Yield | 3.92% |
| Earnings Yield | 20.39% |
| FCF Yield | -3.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Wonbiogen has an Altman Z-Score of 5.47 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.47 |
| Piotroski F-Score | 6 |